Evonik's Lab Breakthroughs Take a Back Seat to the BASF Question Mark

Evonik's RAG-Stiftung weighs BASF interest with no decision, as NRW warns on jobs and the group unveils biodegradable polymers and a pharma award.

Evonik has spent the past week quietly stacking up scientific wins, but the market has its eyes fixed firmly elsewhere. While the Essen-based specialty chemicals group unveiled a biodegradable polymer platform and collected a pharma industry award for its automated research labs, the dominant storyline remains the unresolved takeover interest from Ludwigshafen rival BASF — a saga that has drawn in the company's largest shareholder, a powerful union, and the state government of North Rhine-Westphalia.

A Foundation That Won't Be Rushed

At the heart of any potential deal sits the RAG-Stiftung, Evonik's biggest single investor. According to a Handelsblatt report, the foundation's board of trustees convened an online session on Friday to receive briefings on BASF's interest in the group. No decision on how to proceed emerged from that meeting. That silence matters: without the foundation's blessing, any approach is widely regarded as dead on arrival.

Political headwinds add another layer of resistance. Reuters reported that on October 5, North Rhine-Westphalia's state government made clear that jobs at Evonik and the company's ability to chart its own course must not be jeopardized by any takeover. The fear of losing industrial employment anchors Düsseldorf's stance. The SPD parliamentary group in the state legislature went a step further, floating the idea of the state itself taking a stake in Evonik.

Organized labor has also weighed in. The IGBCE union demanded firm commitments and answers regarding Evonik's sites and workforce on Thursday, sharpening the pressure on management from yet another direction.

BASF Signals Interest, Evonik Signals Silence

Reports of a sweeter offer from BASF continue to circulate. Reuters, citing two sources close to the Ludwigshafen group, said BASF could improve its previously rejected bid should talks materialize. Evonik's response was unambiguous: no negotiations are currently underway, and no higher offer has been confirmed. That gap between market chatter and corporate reality has become the defining tension of the stock.

It leaves the management team in an awkward spot. Executives are pressing ahead with their own strategic agenda, yet the equity is being valued largely through an M&A lens — a disconnect between operational substance and deal-driven expectation that colors nearly every trading session.

Berenberg Shifts Its Stance

Analysts have taken note of the changed landscape. On October 5, private bank Berenberg upgraded Evonik from "Sell" to "Hold" and lifted its price target from EUR 15.50 to EUR 20. The analysts explicitly tied the revision to BASF's takeover interest.

The stock closed Friday at EUR 21.42, just shy of the 52-week high of EUR 21.62 touched during the same session. Evonik's market capitalization stands at EUR 9.79 billion. Fresh fundamental data arrives on November 3, 2026, when the company reports third-quarter results.

Meanwhile, the Science Keeps Moving

Away from the ownership debate, Evonik is advancing its own research and digitization agenda. On October 5, the group announced a biodegradable polymer platform intended as the basis for future generations of functional EUDRAGIT excipients, which are used for oral drug delivery. Non-commercial laboratory quantities are currently being made available for joint development work with selected industry partners.

A day later, at the CPHI trade fair in Milan, Evonik received the CPHI Pharma Award 2026 in the "Digital Transformation" category for its Self Driving Labs, which use digital control to accelerate and streamline process steps in pharmaceutical development. It is a reminder that, for all the takeover noise, the company's operating engine is still running — even if the market, for now, is listening to a different story.